Veneno Technologies has launched a joint research collaboration with Alpha Fusion Inc. and Mitsubishi Tanabe Pharma Corporation to develop innovative cancer therapeutics. By leveraging our proprietary peptide technologies, we aim to accelerate the development of next-generation radiopharmaceuticals that precisely target cancer cells. This collaboration will focus on the research and development of novel astatine-211-labeled radiopharmaceuticals […]

Veneno Technologies has launched a joint research collaboration with Alpha Fusion Inc. and Mitsubishi Tanabe Pharma Corporation to develop innovative cancer therapeutics. By leveraging our proprietary peptide technologies, we aim to accelerate the development of next-generation radiopharmaceuticals that precisely target cancer cells. This collaboration will focus on the research and development of novel astatine-211-labeled radiopharmaceuticals […]

Veneno Technologies has entered into a business alliance with Molmir Inc., a company with strong expertise in identifying and refining drug discovery seeds originating from academia, to build a new commercialization model that ensures academic drug discovery does not end at the research stage. As academia-originated ventures are becoming increasingly central players in drug discovery, […]